Patents by Inventor Constance M. John

Constance M. John has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for preventing and treating damage to the heart
    Patent number: 11179439
    Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: November 23, 2021
    Assignees: MandalMed, Inc., The Regents of the University of California
    Inventors: Constance M. John, Meenakshi Gaur, Matthew L. Springer, Xiaoyin Wang
  • METHODS AND COMPOSITIONS FOR PREVENTING, TREATING, AND REVERSING LIVER FIBROSIS
    Publication number: 20210353715
    Abstract: Methods of reducing, treating, or reversing liver fibrosis in a subject in need thereof comprising administering Galectin-3C, are provided. Also provided are Galectin-3C fusion proteins with increased stability.
    Type: Application
    Filed: September 19, 2019
    Publication date: November 18, 2021
    Applicant: MandalMed, Inc.
    Inventors: Constance M. JOHN, Khalil MOUNZIH
  • Proliferative primary human Sertoli cell cultures and their applications
    Patent number: 10851348
    Abstract: Technology for the isolation and propagation of primary human Sertoli cells from normal testes tissue, including cultures of proliferative primary human Sertoli cells for research and clinical applications, and a pharmaceutical composition for cell therapy, ex vivo gene therapy, and for the reduction of autoimmune, allograft, and xenograft immune reactions.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: December 1, 2020
    Assignee: MANDALMED, INC.
    Inventors: Constance M. John, Alpa Mahuvakar
  • METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING DAMAGE TO THE HEART
    Publication number: 20200246427
    Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.
    Type: Application
    Filed: June 18, 2019
    Publication date: August 6, 2020
    Applicants: MandalMed, Inc., The Regents of the University of California
    Inventors: Constance M. JOHN, Meenakshi GAUR, Matthew L. SPRINGER, Xiaoyin WANG
  • Methods and compositions for preventing and treating damage to the heart
    Patent number: 10369195
    Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: August 6, 2019
    Assignees: MandalMed, Inc., The Regents of the University of California
    Inventors: Constance M. John, Meenakshi Gaur, Matthew L. Springer, Xiaoyin Wang
  • METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING DAMAGE TO THE HEART
    Publication number: 20180042993
    Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.
    Type: Application
    Filed: August 1, 2017
    Publication date: February 15, 2018
    Inventors: Constance M. JOHN, Meenakshi GAUR, Matthew L. SPRINGER, Xiaoyin WANG
  • PROLIFERATIVE PRIMARY HUMAN SERTOLI CELL CULTURES AND THEIR APPLICATIONS
    Publication number: 20170114327
    Abstract: Technology for the isolation and propagation of primary human Sertoli cells from normal testes tissue, including cultures of proliferative primary human Sertoli cells for research and clinical applications, and a pharmaceutical composition for cell therapy, ex vivo gene therapy, and for the reduction of autoimmune, allograft, and xenograft immune reactions.
    Type: Application
    Filed: September 27, 2016
    Publication date: April 27, 2017
    Inventors: Constance M. JOHN, Alpa MAHUVAKAR
  • Proliferative Primary Human Sertoli Cell Cultures And Their Applications
    Publication number: 20090028833
    Abstract: Technology for the isolation and propagation of primary human Sertoli cells from normal testes tissue, including cultures of proliferative primary human Sertoli cells for research and clinical applications, and a pharmaceutical composition for cell therapy, ex vivo gene therapy, and for the reduction of autoimmune, allograft, and xenograft immune reactions.
    Type: Application
    Filed: January 26, 2007
    Publication date: January 29, 2009
    Inventors: Constance M. John, Alpa Mahuvakar
  • N-terminally truncated galectin-3 for use in treating cancer
    Patent number: 6770622
    Abstract: There is provided a composition having an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating cancer by administering to a patient in need of such treatment an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: August 3, 2004
    Inventors: Gary A. Jarvis, Constance M. John, Hakon Leffler
  • Biologic modulations with nanoparticles
    Publication number: 20040023855
    Abstract: Small particles are disclosed for use in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. A particle having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target are also disclosed. Compositions and methods of use are also set forth.
    Type: Application
    Filed: April 8, 2003
    Publication date: February 5, 2004
    Inventors: Constance M. John, Gretchen Unger
  • N-terminally truncated galectin-3 for use in treating cancer
    Publication number: 20030054982
    Abstract: There is provided a composition having an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating cancer by administering to a patient in need of such treatment an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 8, 2001
    Publication date: March 20, 2003
    Inventors: Gary A. Jarvis, Constance M. John, Hakon Leffler